Covidien received FDA clearance for its HawkOne atherectomy device that’s intended for treatment of peripheral arterial disease (PAD). The HawkOne features a newly designed cutting mechanism for removing of all types of intraarterial plaque.
“Covidien is committed to being the clear first choice for our physician and hospital partners by delivering new innovative technologies that help save and improve patient lives,” in a statement said Brian Verrier, president, Peripheral Vascular, Covidien. “The FDA clearance of the HawkOne™ system enhances our leading peripheral vascular portfolio and further demonstrates Covidien’s leadership in the atherectomy space.”
Press release: Covidien’s HawkOne™ Directional Atherectomy System Receives FDA 510(K) Clearance for the Treatment of Peripheral Arterial Disease…